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Epidemiology of Oral Contraceptives and
Cardiovascular Disease
To the Editor: Chasan-Taber and Stampfer (1) present the
"recency of market introduction" äs a potential source of bias in
evaluating the risk for venous thrombosis associated with new
oral contraceptives containing desogestrel or gestodene. The ar-
gument is that women receiving these puls started using them
more recently, those receiving older contraceptives had been
using them for a longer time, and the risk for thrombosis is
higher in the early periods of use. The straightforward solution is
to compare "like with like": women who are receiving different
brands for similar time periods. This analysis was done by Jick
and colleagues (2), who found that in the first 6 months of use,
women receiving desogestrel and gestodene contraceptives have a
sixfold to ninefold greater risk for venous thrombosis relative to
women receiving levonorgestrel contraceptives. In several other
studies, separate analyses showed that relative risk was increased
rather than decreased in the first period of use (3). The correct
Interpretation of these Undings is that the excess risk of deso-
gestrel and gestodene contraceptives cannot be explained by
"recency of introduction bias" because the effect does not disap-
pear upon stratiflcation. The higher excess risk in the first period
of use indicates effect modification and supports the decision of
the British and German authorities to caution against first-time
prescription of these pills to young women.
Chasan-Taber and Stampfer misquote our paper: In the Lei-
den Thrombophilia Study, we did find the highest risk in the
youngest users (4), in line with the data reported above. Because
of the complexity of the issue, the World Health Organization
convened an international group of independent scientists in
• November 1997. The main conclusions of their report, one of
which is that contraceptives containing desogestrel or gestodene
carry a risk for thrombosis beyond that of contraceptives con-
taining levonorgestrel, have recently become available (5).
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In response: Vandenbroucke and colleagues state that we present
the "recency of market introduction" äs a potential source of bias in
evaluating the risk for venous thromboembolism associated with
oral contraceptives containing the new progestogens. They mis-
construed our argument äs stating that the risk for thrombosis is
"higher in the early periods" of use and then declines over time.
We instead suggest that clinicians prescribe newly introduced
drugs to a population different from the population receiving
more established drugs. Thus, the relative risk for venous throm-
boembolism in users of new drugs may be elevated because the
population to whom new drugs are prescribed has a higher
baseline risk. The excess risk observed by Bloemenkamp and
colleagues (1) in younger women (a population in which most
new users will be found) further supports this argument.
With banner headlines carrying the government's warning,
there can be little doubt that many women either switched for-
mulations or discontinued use of oral contraceptives, leading to
increased rates of unplanned pregnancies and abortion. The Brit-
ish Pregnancy Advisory Service, which provides nearly 20% of
abortions in the United Kingdom, reported a 10% increase in the
number of abortions performed after the government's warning.
Of women surveyed, 40% reported discontinuing oral contracep-
tive use immediately after the warning (2). A decrease in rates of
thromboembolic disease after this sensational announcement has
not been shown. A more moderate approach may have been
better.
We agree that the evidence does suggest, although not con-
firm, an increased risk for thromboembolic disease associated
with use of the newest progestogens. This apparent increase in
risk cannot be dismissed äs a result of bias, but neither has it
been confirmed. The strength of the evidence and the appropri-
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